Table 1. Clinicopathologic features and survival outcomes of patients (N = 61).
| Characteristics | N | % |
|---|---|---|
| Age | ||
| Median | 60 | |
| Range | 33–80 | |
| Sex | ||
| Male | 40 | 65.6 |
| Female | 21 | 34.4 |
| ECOG performance status | ||
| 0 | 31 | 50.8 |
| 1 | 22 | 36.1 |
| 2 | 8 | 13.1 |
| WHO classification | ||
| Adenocarcinoma well differentiated | 5 | 8.2 |
| Adenocarcinoma moderately differentiated | 37 | 60.7 |
| Adenocarcinoma poorly differentiated | 14 | 23 |
| Signet ring cell | 5 | 8.2 |
| Prior gastrectomy | ||
| Subtotal gastrectomy | 8 | 13.1 |
| Total gastrectomy | 7 | 11.5 |
| Not done | 46 | 75.4 |
| Primary tumor location | ||
| Gastroesophageal junction | 4 | 6.6 |
| Cardia | 10 | 16.4 |
| Body/Antrum | 47 | 77 |
| HER2 overexpression by IHC | ||
| 2+ | 15 | 24.6 |
| 3+ | 46 | 75.4 |
| HER2/CEP17 ratio by SISH or FISH | ||
| 2.0-4.69 | 11 | 18.0 |
| ≥ 4.7 | 11 | 18.0 |
| Not determined | 39 | 63.9 |
| Metastatic location | ||
| Lymph node | 47 | 77.0 |
| Liver | 27 | 44.3 |
| Peritoneum* | 17 | 27.9 |
| Lung | 8 | 13.1 |
| Bone | 5 | 8.2 |
| Chemotherapy regimen | ||
| Herceptin + FP | 9 | 14.8 |
| Herceptin + XP | 52 | 85.2 |
| Follow-up, months | ||
| Median | 24.3 | |
| Interquartile range | 18.3–28.3 | |
| Progression-free survival, months | ||
| Events (Progression or Death) | 54 | 88.5 |
| Median | 8.0 | |
| 95% CI | 6.8–9.3 | |
| Overall survival, months | ||
| Events (Death) | 35 | 57.4 |
| Median | 16.0 | |
| 95% CI | 11.2–21.0 | |
Abbreviations: CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; WHO, World Health Organization; HER2, human epidermal growth factor receptor 2; IHC, immunohistochemistry; CEP17, chromosome 17 centromere; SISH, silver in situ hybridization; FISH, fluoroscence in situ hybridization; FP, 5-FU+Cisplatin; XP, Xeloda+Cisplatin. *11 patients had measurable peritoneal seeding nodules.